J
Jingwei Li
Researcher at The George Institute for Global Health
Publications - 50
Citations - 1169
Jingwei Li is an academic researcher from The George Institute for Global Health. The author has contributed to research in topics: Canagliflozin & Type 2 diabetes. The author has an hindex of 13, co-authored 44 publications receiving 671 citations. Previous affiliations of Jingwei Li include Third Military Medical University & Stanford University.
Papers
More filters
Journal ArticleDOI
The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis.
TL;DR: The severity of COVID-19 is associated with acute cardiac injury, and acute cardiac injuries are associated with death, which highlights the need to effectively monitor heart health to prevent myocarditis in patients infected with CO VID-19.
Journal ArticleDOI
miR-138 protects cardiomyocytes from hypoxia-induced apoptosis via MLK3/JNK/c-jun pathway
TL;DR: This study demonstrates that up-regulation of miR-138 plays a protective role in myocardial adaptation to chronic hypoxia, which is mediated mainly by MLK3/JNK/c-jun signaling pathway.
Journal ArticleDOI
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.
Christopher P. Cannon,Vlado Perkovic,Vlado Perkovic,Rajiv Agarwal,James Baldassarre,George L. Bakris,David M. Charytan,Dick de Zeeuw,Robert Edwards,Tom Greene,Hiddo J.L. Heerspink,Meg Jardine,Meg Jardine,Adeera Levin,Jingwei Li,Bruce Neal,Bruce Neal,Bruce Neal,Carol A. Pollock,David C. Wheeler,Hong Zhang,Bernard Zinman,Kenneth W. Mahaffey +22 more
TL;DR: It is hypothesized that there would be similar benefits on CV and renal endpoints regardless of baseline HbA1c, including those with Hb a1c <7%.
Journal ArticleDOI
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
Jingwei Li,Jingwei Li,Mark Woodward,Mark Woodward,Mark Woodward,Vlado Perkovic,Gemma A. Figtree,Gemma A. Figtree,Hiddo J.L. Heerspink,Kenneth W. Mahaffey,Dick de Zeeuw,Frank Vercruysse,Wayne Shaw,David R. Matthews,Bruce Neal,Bruce Neal,Bruce Neal +16 more
TL;DR: The mediators that were identified support existing and novel hypothesized mechanisms for the prevention of heart failure with sodium glucose cotransporter 2 inhibitors.
Journal ArticleDOI
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial.
Megumi Oshima,Megumi Oshima,Brendon L. Neuen,Jingwei Li,Vlado Perkovic,David M. Charytan,Dick de Zeeuw,Robert Edwards,Tom Greene,Adeera Levin,Kenneth W. Mahaffey,Luca De Nicola,Carol A. Pollock,Norman Rosenthal,David C. Wheeler,David C. Wheeler,Meg Jardine,Meg Jardine,Hiddo J.L. Heerspink,Hiddo J.L. Heerspink +19 more
TL;DR: In people with type 2 diabetes and CKD, use of canagliflozin results in early, sustained reductions in albuminuria, which were independently associated with long-term kidney and cardiovascular outcomes.